The mission of the MSCP SPORE Career Development Program (CDP) is to stimulate basic, translational, and clinical research by recruiting and supporting new investigators in the area of melanoma and other skin cancers. The CDP provides financial resources for this mission, while the SPORE itself provides a supportive and stimulating research environment. In the previous MSCP SPORE grant period, we supported 7 CDP awardees, all but one of whom were early-stage investigators (one Research Associate, one Research Instructor, and four Assistant or Research Assistant Professors);5 of our 7 CDP awardees were women. All CDP Awardees have experienced success in advancing their careers, publishing their work, and obtaining extramural funding. We will continue to solicit proposals twice per year and to use a peer-reviewed scoring system to prioritize proposals for funding. The CDP Co-Directors, Executive Committee, and Internal and External Advisory Board members participate in the review process, together with the Patient Advocates and additional experts who may be called upon if special reviewer expertise is necessary. The CDP will track progress of the successful applications and provide advisors to funded investigators to ensure that they obtain any needed services from the MSCP SPORE Cores (Administrative Core A;Biospecimen Core B;Biostatistics Core C;and Informatics Core D) and that they are integrated into the SPORE program. Awardees present their research results to the SPORE investigators after one year of support to be eligible for a second year of support. Progress toward translation as well as impact and innovation will determine whether CDP projects are found to merit promotion to full SPORE projects. Awardees will also be advised as appropriate in the preparation of grant applications for funding outside the SPORE mechanism and given access to Core resources to aid in this endeavor.
The MSCP SPORE will identify and support investigators new to research in melanoma and skin cancer with both pilot study funding and expertise and assistance in planning and preparing grant applications for independent funding.
|Dulmage, B O; Feng, H; Mirvish, E et al. (2015) Black cat in a dark room: the absence of a directly oncogenic virus does not eliminate the role of an infectious agent in cutaneous T-cell lymphoma pathogenesis. Br J Dermatol 172:1449-51|
|Sabbatino, Francesco; Wang, Yangyang; Wang, Xinhui et al. (2014) PDGFR? up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget 5:1926-41|
|Tarhini, Ahmad A; Edington, Howard; Butterfield, Lisa H et al. (2014) Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 9:e87705|
|Ng, Yuen-Keng; Lee, Jia-Ying; Supko, Kathryn M et al. (2014) Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res 24:207-18|
|Tarhini, Ahmad A; Shin, Donghoon; Lee, Sandra J et al. (2014) Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res 24:150-7|
|Pancoska, Petr; Kirkwood, John M; Bouros, Spyros et al. (2014) A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon. PLoS One 9:e86375|
|Tarhini, Ahmad A; Lin, Yan; Yeku, Oladapo et al. (2014) A four-marker signature of TNF-RII, TGF-?, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med 12:19|
|Geskin, Larisa J; Akilov, Oleg E; Lin, Yan et al. (2014) Distinct age-matched serum biomarker profiles in patients with cutaneous T-cell lymphoma. Exp Dermatol 23:598-600|
|Schowalter, Michael K; Dulmage, Brittany O; Ho, Jonhan et al. (2014) Comparative proteomic analysis reveals unique tumor protein composition among the melanoma subtypes pure desmoplastic and superficial spreading. Melanoma Res 24:397-400|
|McArthur, Grant A; Chapman, Paul B; Robert, Caroline et al. (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323-32|
Showing the most recent 10 out of 59 publications